BDBM569240 US11427563, Compound 107::US11427563, Compound 112::US11427563, Compound 132::US11427563, Compound 133::US11427563, Compound 140::US11427563, Compound 6

SMILES Clc1cncc2ccc(NC(=O)[C@@H]3CC3c3ccc(cc3)S(=O)(=O)Nc3ncccn3)cc12

InChI Key InChIKey=UAHMLABNZNESHG-UHFFFAOYSA-N

Data  40 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 40 hits for monomerid = 569240   

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 1.5nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 470nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 128nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 68nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 194nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 194nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 68nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 68nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.700nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 1.5nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 128nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.700nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.700nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.700nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 68nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 1nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 1.5nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.25nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.25nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.25nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.800nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 128nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 128nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 4.10nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 12nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 12nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 4.10nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 4.10nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 4.10nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.950nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 470nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 2nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 2nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 2nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 1.5nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 2.90nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 2.90nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 1.5nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 1.5nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 1.5nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent